Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* 40 - 80 years of age~* Fluency in written and spoken English~* Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods~* Current/former smokers with at least a 10 pack-year history of cigarette smoking~* A measured post-salbutamol FEV1/FVC ratio of \< or = 0.70~* A measured post-salbutamol FEV1 \> or = 40 and \< or = 80% of predicted normal values~* Demonstrated reversibility to a short acting beta agonist by either \>12% and \>150 ml improvement in baseline FEV1, 30 minutes following administration of 4 puffs of salbutamol MDI or an absolute improvement of \>200 ml in baseline FEV1, 30 minutes following administration of 4 puffs of salbutamol MDI.~* Competent at using the inhalation device~Exclusion Criteria:~* Women who are pregnant or lactating~* Primary diagnosis of asthma~* Alpha-1 antitrypsin deficiency as the cause of COPD~* Active pulmonary diseases~* Prior lung volume reduction surgery~* Abnormal chest X-ray (or CT scan) not due to the presence of COPD~* Hospitalized due to poorly controlled COPD within 24 weeks of Screening~* Poorly controlled COPD in prior 6-weeks, defined as the occurrence of acute worsening of COPD requiring corticosteroids or antibiotics or acute worsening of COPD requiring treatment prescribed by a physician~* Clinically significant medical conditions~* Lower respiratory tract infection requiring antibiotics in past 6 weeks~* Clinically significant abnormal ECG~* Clinically significant uncontrolled hypertension~* Positive Hepatitis B surface antigen or Hepatitis C antibody~* Cancer that has not been in complete remission for at least 5 years~* History of hypersensitivity to any beta2-agonists or any study drug component~* History of severe milk protein allergy~* Known or suspected history of alcohol or drug abuse~* Medically unable to withhold short acting bronchodilators for 8-hours~* Use of the medications below in specified time interval prior to Screening: 12-weeks: depot corticosteroids, intra-articular corticosteroids; 4 weeks: ICS \>1000 μg/day of fluticasone propionate or equivalent, non-potassium sparing diuretics, P-glycoprotein inhibitors, CYP3A4 inhibitors; 1 week: tiotropium; 48 hours: oral beta agonists, long acting beta agonists, theophylline, zariflukast, montelukast, zileuton; 8 hours: ipratropium or ipratropium/salbutamol combination product, inhaled short acting beta agonists, xanthine containing foods~* Use of the following medications is prohibited: tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, beta-adrenergic antagonists, anticonvulsants (barbiturates,hydantoins, and carbamazepine and phenothiazines~* Receiving long-term-oxygen or nocturnal oxygen therapy for \>12 hours a day~* Diagnosis of sleep apnea that is uncontrolled~* Participation in acute phase of pulmonary rehabilitation in prior 4 weeks or will enter acute phase of pulmonary rehabilitation program during study~* Unable to comply with study procedures~* Affiliated with Investigator site~* Questionable validity of consent~* A positive drug of abuse test at Screening lives prior to Screening, whichever is longer

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Inhaled PT005 2.4 mcg
- 2 (Type: EXPERIMENTAL): Inhaled PT005 4.8 mcg
- 3 (Type: EXPERIMENTAL): Inhaled PT005 9.6 mcg
- 4 (Type: PLACEBO_COMPARATOR): Inhaled Placebo
- 5 (Type: ACTIVE_COMPARATOR): Formoterol Fumarate 12 mcg (Foradil Aerolizer)

Based on this trial design, predict the completion outcome and termination type (if applicable).